Jim Cramer on Bristol-Myers Squibb. Co (NYSE:BMY): They Should Have Known Better
We recently published a list of Jim Cramer Discusses These 11 Stocks & Reveals Why Tech Stocks Are Down. In this article, we ...
Bristol-Myers Squibb (NYSE:BMY) Sees Rising Interest in Sotyktu Despite 3% Share Price Dip
Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating ...
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Shares of Bristol Myers Squibb Co. BMY advanced 1.90% to $60.02 Friday, on what proved to be an all-around dismal trading ...
Why Bristol-Myers Squibb Co. (BMY) Went Up On Friday?
We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...
Crain's New York Business1d
Bristol-Myers CEO awarded $19M after a difficult year
Bristol-Myers Squibb awarded its CEO nearly $19 million in compensation for 2024, following a challenging year for the ...
Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold
BMY has enjoyed robust capital appreciation over the past few months, significantly aided by the ongoing market rotation to ...
Medical Dialogues15h
Bristol Myers Squibb gets Positive EMA Committee opinion for subcutaneous formulation of Opdivo across Multiple Solid Tumor Indications
Princeton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors
This was the stock's second consecutive day of losses.
Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy
Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...
Bristol Myers announces CHMP opinion recommending Opdivo combination approval
Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...
Bristol Myers announces CHMP recommendation for Opdivo formulation approval
Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...